The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending booster shots.

RSV vaccines could get broader CDC backing for adults aged 50-59 at risk after an endorsement from an agency's expert panel. Read more here.

A key group of government advisers voted to expand the use of vaccines for a common respiratory illness, providing a boost to ...

RSV typically causes cold-like symptoms, but is also a leading cause of pneumonia in toddlers and older adults. An estimated ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

Parts of DaVita's network were locked down by the attack, and the company has not yet provided a timeline for recovery. DaVita works with over 700 U.S. hospitals providing kidney dialysis. In pharma ...

A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older ...

Vinay Prasad, a hematologist-oncologist known for his vocal opposition to elements of the Covid response, also jumped on Cavazzoni’s move back to Pfizer in a same-day blog post titled “FDA approves ...

As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and ...

Shares of several major pharmaceutical companies slumped Wednesday morning as President Donald Trump threatened tariffs on ...